LOS ANGELES — Niagen Bioscience Inc. has launched Niagen Plus, a clinician-directed telehealth platform that allows eligible U.S. patients to access prescription-only, pharmaceutical-grade Niagen from home through a new at-home injection kit.
The company said the launch marks its first direct-to-client access model and expands Niagen Plus beyond clinic visits. The platform introduces at-home subcutaneous administration of Niagen, the company’s patented nicotinamide riboside chloride, known as NRCl, which is intended to support NAD+ levels tied to cellular and tissue health.
Niagen Bioscience said the telehealth program guides patients through an online medical intake and consultation with a licensed provider. Eligible patients may receive a prescription for the Niagen At-Home Injection Kit, which is dispensed by a licensed 503A pharmacy and shipped directly to the patient.
“With this launch, we are expanding access to Niagen through a clinician-directed telehealth model designed around quality, convenience, and clinical oversight,” said Rob Fried, Chief Executive Officer of Niagen Bioscience. “We are introducing a new way for eligible patients to access pharmaceutical-grade Niagen from home while staying grounded in the scientific rigor, quality standards, and disciplined approach that define Niagen Bioscience.”
The Niagen At-Home Injection Kit is designed for subcutaneous use and includes a sterile 500 mg vial of Niagen powder, bacteriostatic water for reconstitution, injection syringes, a mixing syringe and needle, alcohol prep pads and step-by-step instructions accessible by QR code. The company said the compounded kit is manufactured under cGMP standards using pharmaceutical-grade components and follows clinician-directed 50 mg or 100 mg dosing protocols, as prescribed.
“What I find compelling here is the emphasis on process and quality,” said Dr. Chris Meletis, Former Dean and Chief Medical Officer of National College of Natural Medicine (NCNM) and advisor to Niagen Bioscience. “This is not a casual direct-to-consumer purchase. It is a clinician-directed telehealth program designed to evaluate eligibility and, when appropriate, provide prescription access to pharmaceutical-grade Niagen in an at-home format.”
Niagen Bioscience said the product was generally considered safe and well-tolerated in a clinical safety trial, with no significant adverse effects reported at 50 mg/mL and 100 mg/mL doses during the study. The company said injectable administration bypasses gut metabolism and may offer a more direct delivery pathway, with preclinical models suggesting potential for greater tissue availability.
The launch comes as the market for injectable therapies and longevity-related products continues to expand. Niagen Bioscience cited Future Market Insights data valuing the U.S. injectable industry at $223.6 billion in 2025, with projected growth of about 6.8% annually through 2035. The company also cited SNS Insider projections that the U.S. longevity market could grow from $9.16 billion in 2025 to $20.17 billion by 2035.
